GeneCentric Diagnostics

Bristol-Myers Squibb, GeneCentric Diagnostics collaborate

Friday, January 6, 2017

Bristol-Myers Squibb and GeneCentric Diagnostics has announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials. Additionally, GeneCentric announced it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP and build-out of GeneCentric’s new laboratory in Research Triangle Park.

[Read More]